To include your compound in the COVID-19 Resource Center, submit it here.
ALT said that in a double-blind, placebo-controlled U.S. Phase IIa study, patients receiving 210 mg
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury